First Daily GLP-1 Pill Approved: Wegovy Oral Achieves 17% Weight Loss in Trial

On 11 June 2026, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved the first daily oral GLP-1 receptor agonist for weight management, Wegovy® pill (semaglutide tablets), marking a significant expansion of the obesity pharmacotherapy toolkit. Manufactured by Novo Nordisk, the tablet is indicated as an adjunct to diet and exercise for adults with obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) and at least one weight-related comorbidity. The approval reshapes a market previously dominated by injectable semaglutide (Wegovy 2.4 mg once-weekly) and other GLP-1 agents, offering a needle-free option that may improve patient acceptance and adherence. The decision is underpinned by the OASIS 4 phase 3 trial, in which 307 adults without diabetes received oral semaglutide 25 mg daily or placebo. When assessed on the full analysis set (regardless of adherence), the treatment group lost 13.6% of body weight versus 2.4% for placebo after 64 weeks, a treatment difference of 11.2 percentage points. In the per-protocol analysis (adherent participants), weight loss reached 16.6% versus 2.7% placebo, equating to a 13.9 point advantage. These figures are comparable to those seen with injectable high-dose GLP-1 regimens, positioning the pill as a formidable competitor not only to existing injectables but also to emerging oral rivals from other pharmaceutical companies. The side-effect profile is consistent with the GLP-1 class: 74.0% of oral semaglutide recipients experienced gastrointestinal symptoms—nausea, vomiting, diarrhoea—compared with 42.2% on placebo. Importantly, these events were mostly mild to moderate and transient, with a discontinuation rate of 6.9% due to adverse events, similar to injectable semaglutide trials. The dosing regimen requires upward titration from 1.5 mg to 25 mg over several months, with administration on an empty stomach after at least eight hours of fasting and a 30-minute post-dose no-food window, adding a behavioural compliance layer that will need patient education. From a public health perspective, the approval addresses critical unmet need in the UK, where obesity prevalence exceeds 25% of adults. The pharmaceutical weight-management market has boomed with injectable GLP-1s, but stigma, needle phobia, and cold-chain storage requirements have limited uptake. An oral alternative could democratise access, though the immediate path is constrained: the pill will be available privately within weeks but has not yet been evaluated by the National Institute for Health and Care Excellence (NICE) for NHS commissioning. This creates a two-tier access scenario where only those who can afford private prescriptions—likely priced at a premium—will benefit in the short term. Novo Nordisk UK general manager Sebnem Avsar Tuna called the pill a milestone offering “choice and flexibility,” while Professor Naveed Sattar of the University of Glasgow hailed it as “welcome news” that may address needle aversion. Market implications for Novo Nordisk are substantial. The company solidified its GLP-1 franchise with the injectable Wegovy and oral Rybelsus (lower-dose semaglutide for diabetes); this higher-dose weight-loss pill extends its commercial runway and presents a new growth vector, particularly if it secures NHS reimbursement. However, competitors such as Eli Lilly (orforglipron, an oral non-peptide GLP-1) and Pfizer (danuglipron) are advancing their own oral candidates, meaning the first-mover advantage in the UK is time-sensitive. The company’s shares (NYSE: NVO) have historically reacted positively to regulatory milestones, and today’s announcement may reinforce investor confidence in the obesity portfolio. Forward-looking, the pill’s success will depend on real-world adherence, payer negotiations, and pharmacovigilance for rare adverse events. The oral semaglutide label includes warnings about absorption interference (e.g., timing of food and other oral medications), which could pose a challenge in polypharmacy patients—a common scenario in the target population with comorbidities like hypertension or dyslipidaemia. Additionally, the absence of long-term cardiovascular outcomes data for this specific dose (the SELECT trial used weekly injectable semaglutide) may temper enthusiasm among payers until more evidence emerges. Nonetheless, the MHRA approval validates the concept of daily oral GLP-1 therapy for obesity and sets a precedent that other regulators globally will likely follow, intensifying the race to capture an obesity market projected to exceed $100 billion by 2030.